Evaluating Reboxetine and Methylphenidate for Attention, Sensory, and Emotional Challenges in Adults with PTSD

What this Trial Is About

Researchers are studying adults aged 20 to 60 with Posttraumatic Stress Disorder PTSD to understand attentional, sensory, and emotional difficulties linked to the condition. The study evaluates how attention, emotional regulation, and sensory processing relate in PTSD patients, comparing them to healthy controls. It also investigates the effects of the drugs reboxetine and methylphenidate on these symptoms using a randomized, double-blind controlled trial. Participants with PTSD will be randomly assigned to receive either active treatment with reboxetine and methylphenidate or a placebo. Reboxetine is taken daily starting at 2 mg for three days, then increased to 4 mg for 26 days. On day 22, methylphenidate or placebo 10 mg is administered twice daily for four days under clinic observation. The placebo group follows the same medication schedule without active drugs. Throughout the study, participants undergo various assessments including brain activity measurements with functional near-infrared spectroscopy and electroencephalography, attention tests, sensory and executive function questionnaires, and quality of life surveys. The main outcome compares PTSD symptom changes before and after treatment using the Clinician-Administered PTSD Scale. Safety is monitored during medication dosing, with the study lasting approximately 26 days for each participant.

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD